AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15911727
Drug: Treatment costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment costs of $37
Trial: 15911727
Drug: Treatment costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment costs of $68
Trial: 15911727
Drug: Treatment costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment costs of $162
Trial: 15911727
Drug: Treatment costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment costs of $589
Trial: 10697395
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (streptokinase or tissue-type plasminogen activator)
Trial: 6110093
Drug: LM24056 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM24056 at 100 mg
Trial: 6110093
Drug: LM24056 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM24056 at 200 mg
Trial: 6110093
Drug: LM24056 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM24056 at 300 mg
Trial: 31984963
Drug: Artmaking with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artmaking with fluid materials (e.g., finger paints)
Trial: 31984963
Drug: Artmaking with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artmaking with less fluid materials (e.g., gouache paint with a brush)
Trial: 25213048
Drug: Fluticasone furoate-vilanterol
RxNorm normalized name: Fluticasone Furoate-Vilanterol Ellipta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate-vilanterol 100-25 mcg
Trial: 25213048
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 100 mcg
Trial: 21918905
Drug: Colchicine 1
RxNorm normalized name: colchicine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg per day
Trial: 18156033
Drug: Budesonide plus
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide plus formoterol maintenance and reliever therapy
Trial: 18156033
Drug: Fixed-dose budesonide
RxNorm normalized name: budesonide Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose budesonide plus formoterol
Trial: 18156033
Drug: Fixed-dose fluticasone
RxNorm normalized name: fluticasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose fluticasone plus salmeterol
Trial: 2744909
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) 400 mg/day for 13 days
Trial: 2744909
Drug: Phenytoin 300
RxNorm normalized name: phenytoin 300 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 300 mg/day for 13 days
Trial: 105970
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (200 mg qds)
Trial: 8030597
Drug: Taurine 10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine 10.8 mg/kg ideal body weight (group 2)
Trial: 8030597
Drug: Taurine 50
RxNorm normalized name: taurine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine 50 mg/kg ideal body weight (group 3)
Trial: 2729161
Drug: PPBG less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPBG less than 13 mmol/L
Trial: 2729161
Drug: PPBG greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPBG greater than 13 mmol/L
Trial: 2729161
Drug: Exclusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusion of participants with PPBG greater than 13 mmol/L
Trial: 23698160
Drug: Folate enriched
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate enriched diet (200 μg)
Trial: 23698160
Drug: 5-MTHF (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-MTHF (200 μg)
Trial: 23698160
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (200 μg)
Trial: 20647200
Drug: Lorcaserin 10
RxNorm normalized name: lorcaserin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg twice daily for 52 weeks
Trial: 12517200
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of reliever medications
Trial: 12517200
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of controller medications
Trial: 7137522
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA) 100 mg sustained-release preparation
Trial: 7137522
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA) 50 mg combined with antihistamine
Trial: 7137522
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) 5 mg
Trial: 7137522
Drug: PPA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA (100 mg) and combined preparation containing PPA (50 mg) taken twice a day
Trial: 30527555
Drug: Guardix® (liquid-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guardix® (liquid-based hyaluronic acid and carboxymethyl cellulose solution)
Trial: 16269298
Drug: Bariatric operation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bariatric operation (not specified dosage or duration)
Trial: 12162474
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg x 3, q4-6h)
Trial: 1972947
Drug: 2% calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% calcium mupirocin ointment after tincture of iodine
Trial: 7439516
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose combination of slow-release aminophylline and salbutamol
Trial: 29798201
Drug: Binglianqingye Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binglianqingye Spray
Trial: 29798201
Drug: Jinsangzi Tablet
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.25 g in 100 mL TOPICAL LIQUID [Jinlingzi disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinsangzi Tablet
Trial: 29798201
Drug: Jinhoujian Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinhoujian Spray
Trial: 27108410
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review (PMC) at study start (T-0) and after 28 weeks (T-28)
Trial: 27108410
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review (PMC)
Trial: 18421919
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy (WBCT) for 120-180 seconds at temperatures between -110°C and -160°C, 15 treatments over 3 weeks.
Trial: 18421919
Drug: Standard psychopharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychopharmacological treatment (not specified)
Trial: 15206496
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (10 mg/day enalapril and 50 mg/day losartan)
Trial: 15206496
Drug: Double-dose monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose monotherapy (20 mg/day enalapril or 100 mg/day losartan)
Trial: 15206496
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (enalapril and losartan)
Trial: 1102260
Drug: Methocarbamol (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methocarbamol (1500 mg. q.d.s.)
Trial: 31545799
Drug: Diazoxide Choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide Choline Controlled-Release Tablets (DCCR)
Trial: 19964499
Drug: Therapist-mediated post-stroke
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-mediated post-stroke rehabilitation using haptic/graphic error augmentation
Trial: 16505324
Drug: LY450139 dihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 dihydrate 30 mg for 1 week followed by 40 mg for 5 weeks
Trial: 2006723
Drug: Bupivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (20 ml 0.25% every 4 h)
Trial: 7096279
Drug: Doxepin HCl
RxNorm normalized name: doxepin HCl
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin HCl (50 mg h.s.)
Trial: 7096279
Drug: Cimetidine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1000 mg/day in divided doses)
Trial: 27007793
Drug: Low-dose spironolactone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spironolactone (25 mg daily)
Trial: 31071047
Drug: 3D-DHD (three-dimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D-DHD (three-dimensional printed dynamic hand device) used twice a week for four weeks, followed by a two-week home program
Trial: 19417110
Drug: Valsartan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (mean dose 114 +/- 41 mg/day)
Trial: 15336471
Drug: Cizolirtine citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cizolirtine citrate 350 mg IV
Trial: 15336471
Drug: Metamizol sodium
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol sodium 2,500 mg IV
Trial: 9730125
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (enoxaparin 40 mg daily) for 7 days
Trial: 22858264
Drug: DBT-based psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBT-based psychoeducational group (BDG) intervention consisting of 12 weekly 90-min sessions teaching DBT skills, mindfulness techniques, and general BD psychoeducation.
Trial: 21163686
Drug: Visible-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visible-light therapy (VLT) device
Trial: 17199681
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (compression alone)
Trial: 9179456
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.05 mg/day x 21 days) and oral progestogens (10 mg/day medroxyprogesterone acetate [MPA] in the last 12 days, 10 mg/day dihydrogesterone in the last 12 days, and 50 mg/day cyproterone in the first 10 days)
Trial: 3531033
Drug: Captopril (Aceten)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (Aceten) 150 mg/day
Trial: 3531033
Drug: M-dopa 750
RxNorm normalized name: (-)-dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-dopa 750 mg/day
Trial: 30282510
Drug: Nexodyn solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexodyn solution on top of standard of care
Trial: 28035345
Drug: High-flavonoid fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavonoid fruit and vegetables (>15 mg/100 g)
Trial: 28035345
Drug: Low-flavonoid fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavonoid fruit and vegetables (<5 mg/100 g)
Trial: 28035345
Drug: High-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol cocoa drink (494 mg total flavanols)
Trial: 28035345
Drug: Low-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol cocoa drink (23 mg total flavanols)
Trial: 22892813
Drug: High flavanols
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanols (≈990 mg per day)
Trial: 22892813
Drug: Intermediate flavanols
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate flavanols (≈520 mg per day)
Trial: 22892813
Drug: Low flavanols
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanols (≈45 mg per day)
Trial: 20635829
Drug: Generic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic medication voucher program providing a 30-day supply of 8 specific medications in addition to academic detailing.
Trial: 20635829
Drug: Generic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic medication voucher program.
Trial: 12629093
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg DHEA (n = 19)
Trial: 12629093
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg DHEA
Trial: 10475655
Drug: Methylprednisolone 250
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 250 mg at induction of anaesthesia, with a further three doses at 6-hourly intervals postoperatively
Trial: 1751266
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and midazolam combination
Trial: 1751266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propofol and midazolam
Trial: 7103030
Drug: Fentanyl with
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl with various anaesthetic agents
Trial: 27630318
Drug: Capecitabine (CCB)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (CCB) alone (1,000 mg/m2 bid p.o.)
Trial: 27630318
Drug: Capecitabine (CCB)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (CCB) plus Cetuximab (CTX) (loading dose 400 mg/m2 followed by 250 mg/m2 weekly i.v. maintenance dose)
Trial: 25158772
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with clopidogrel and aspirin
Trial: 21839429
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 40 mg triamcinolone, 2 ml bupivicaine, and 6 ml sterile water for injection
Trial: 21839429
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 40 mg triamcinolone and 2 ml bupivicaine
Trial: 20421430
Drug: 1.5% dextrose
RxNorm normalized name: Delflex with 1.5% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% dextrose solution
Trial: 15807814
Drug: Pointed microneedle
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pointed microneedle injections
Trial: 15807814
Drug: Symmetric microneedle
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symmetric microneedle injections
Trial: 15807814
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application (TA)
Trial: 10850522
Drug: Intravenous gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gatifloxacin 400 mg
Trial: 10850522
Drug: Oral gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gatifloxacin 400 mg
Trial: 8790227
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone at a dose of 0.025 mg/kg body weight/day administered by daily subcutaneous injection over a 6-month study period
Trial: 8790227
Drug: Estrogen (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (not specified dosage or duration)
Trial: 1637766
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic (2% lignocaine and 0.03 iu/ml octopressin)
Trial: 6398314
Drug: Thymopentin 50
RxNorm normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin 50 mg, i.v., 3 times a week for 3 consecutive weeks
Trial: 22079469
Drug: Oral beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beclomethasone dipropionate (BDP) administered as 1-mg immediate-release formulation plus 1-mg delayed-release formulation orally four times daily.
Trial: 22079469
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as per the study design.
Trial: 22079469
Drug: Overall adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall adherence to the study drug during the first 4 weeks after hematopoietic cell transplantation.
Trial: 22079469
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to the study drug schedule.
Trial: 19153943
Drug: drug-free
RxNorm normalized name: HEAD CARE Proactive Health Drug-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug-free
Trial: 10961470
Drug: Urodynamic examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urodynamic examination before and after delayed treatment starting 6 months after inclusion in the study (Control group)
Trial: 3158563
Drug: Fominoben (PB89)
RxNorm normalized name: fominoben
DrugBank: Fominoben (DB08968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fominoben (PB89) - 160 mg, 3 times a day for 2 weeks
Trial: 3158563
Drug: Dextromethorphan -
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan - 30 mg, 3 times a day for 2 weeks
Trial: 29398337
Drug: 80 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g/d prunes (plus 300 ml/d water)
Trial: 29398337
Drug: 120 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g/d prunes (plus 300 ml/d water)
Trial: 29398337
Drug: Control (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (300 ml/d water)
Trial: 29398337
Drug: 80 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g/d prunes
Trial: 29398337
Drug: 120 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g/d prunes
Trial: 29504445
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression therapy in addition to conventional postoperative rehabilitation
Trial: 29504445
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative rehabilitation without intermittent pneumatic compression therapy
Trial: 27450411
Drug: Azithromycin maintenance
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin maintenance therapy (250/500 mg according to body weight) administered three times a week for 6 months
Trial: 27450411
Drug: Azithromycin maintenance
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin maintenance therapy
Trial: 20648883
Drug: Structured comprehensive
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured comprehensive oral health education (SC‐OHE)
Trial: 20648883
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral health education (Control Group)
Trial: 18386538
Drug: Etoricoxib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (120 mg, tablet)
Trial: 12796154
Drug: Salbutamol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (400 micro g)
Trial: 12796154
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (80 micro g)
Trial: 8864639
Drug: Glimepiride (1-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1-8 mg/day, once daily)
Trial: 3006981
Drug: 40, 80,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40, 80, or 160 mg propranolol (non‐selective blockade)
Trial: 3006981
Drug: 25, 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25, 50, or 100 mg atenolol (beta 1‐selective blockade)
Trial: 9135343
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg kg‐1 (group A)
Trial: 9135343
Drug: Propofol 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4 mg kg‐1 (group B)
Trial: 9135343
Drug: Propofol 5
RxNorm normalized name: propofol 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 5 mg kg‐1 (group C)